Clinical trial • Phase I • Rare Disease|Nephrology
MR-L45 for Autosomal dominant polycystic kidney disease
Phase I trial of MR-L45 for Autosomal dominant polycystic kidney disease. 72 participants.
Overview
- Trial Therapeutic Area
- Rare Disease|Nephrology
- Trial Disease
- Autosomal dominant polycystic kidney disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 20-02-2026
- First CTIS Authorization Date
- 01-04-2026
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 72
Eligibility
Recruits 72 Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent or assent provided..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent or assent provided.
Recruitment
- Planned Sample Size
- 72
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 72
Netherlands
- Earliest CTIS Part Ii Submission Date
- 31-03-2026
- Latest Decision Or Authorization Date
- 01-04-2026
- Processing Time Days
- 1
- Number Of Sites
- 1
- Number Of Participants
- 72
Sites
- Site Name
- Van Swietenlaan 6
- Department Name
- Program Management
- Contact Person Name
- Renger Tiessen
- Contact Person Email
- Renger.Tiessen@iconplc.com
Sponsor
Primary sponsor
- Full Name
- Mironid Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Contract research organisations
- Name
- Pharmaceutical Research Associates Group B.V.
- Responsibilities
- Program Management; site contact (email Renger.Tiessen@iconplc.com)
Investigational products
- Investigational Product Name
- MR-L45
- First In Human
- Yes
Related trials
Other published trials that may interest you.